SGAM
TCRT icon

Smith Group Asset Management’s Alaunos Therapeutics TCRT Stock Holding History

Smith Group Asset Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,433
Closed -$1.09M – 448
2014
Q4 		$1.09M Sell
1,433
-144
-9% -$76.4K 0.04% 179
2014
Q3 		$625K Sell
1,577
-6
-0.4% -$2.89K 0.02% 196
2014
Q2 		$957K Buy
1,583
+565
+56% +$315K 0.04% 182
2014
Q1 		$699K Buy
+1,018
New +$682K 0.03% 191

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Smith Group Asset Management's TCRT Position: Q1 2015 in Review

Smith Group Asset Management sold out of Alaunos Therapeutics (TCRT) in Q1 2015, closing a stake of 1,433 shares — an estimated $1.09M sold.

Smith Group Asset Management first reported a position in TCRT in Q1 2014 and held it in 4 quarters. The position peaked at $1.09M in Q4 2014. 128 funds tracked by Wall St. Rank hold TCRT as of Q1 2015.

  • Smith Group Asset Management reported no remaining Alaunos Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Smith Group Asset Management sold 1,433 Alaunos Therapeutics shares in Q1 2015, an estimated $1.09M.
  • Smith Group Asset Management first reported a position in Alaunos Therapeutics in Q1 2014 and held it in 4 quarters.
  • Smith Group Asset Management's Alaunos Therapeutics position peaked at $1.09M in Q4 2014.
  • 128 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2015.

Based on Smith Group Asset Management's 13F filing for Q1 2015, filed 29 Apr 2015.